Literature DB >> 23008302

Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.

Mikkael A Sekeres1, David P Steensma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23008302     DOI： 10.1200/JCO.2012.44.2962

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.

Authors:  Ashkan Emadi; Mariola Sadowska; Brandon Carter-Cooper; Vishal Bhatnagar; Isabella van der Merwe; Mark J Levis; Edward A Sausville; Rena G Lapidus
Journal:  Leuk Res       Date:  2015-04-30       Impact factor: 3.156

2.  The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.

Authors:  Maria Nieto; Pierre Demolis; Eliane Béhanzin; Alexandre Moreau; Ian Hudson; Beatriz Flores; Henry Stemplewski; Tomas Salmonson; Christian Gisselbrecht; David Bowen; Francesco Pignatti
Journal:  Oncologist       Date:  2016-04-18

3.  Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Authors:  Hartmut Döhner; Michael Lübbert; Walter Fiedler; Loic Fouillard; Alf Haaland; Joseph M Brandwein; Stephane Lepretre; Oumedaly Reman; Pascal Turlure; Oliver G Ottmann; Carsten Müller-Tidow; Alwin Krämer; Emmanuel Raffoux; Konstanze Döhner; Richard F Schlenk; Florian Voss; Tillmann Taube; Holger Fritsch; Johan Maertens
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

Review 4.  Emerging therapeutic drugs for AML.

Authors:  Eytan M Stein; Martin S Tallman
Journal:  Blood       Date:  2015-12-10       Impact factor: 22.113

Review 5.  Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.

Authors:  Andrew M Brunner; David P Steensma
Journal:  Hematol Oncol Clin North Am       Date:  2019-12-11       Impact factor: 3.722

6.  Improved outcome for AML patients over the years 2000-2014.

Authors:  Sarah Bertoli; Suzanne Tavitian; Anne Huynh; Cécile Borel; Sarah Guenounou; Isabelle Luquet; Eric Delabesse; Audrey Sarry; Guy Laurent; Michel Attal; Françoise Huguet; Emilie Bérard; Christian Récher
Journal:  Blood Cancer J       Date:  2017-11-29       Impact factor: 11.037

Review 7.  Decitabine in the treatment of acute myeloid leukemia in elderly patients.

Authors:  Priya Malik; Amanda F Cashen
Journal:  Cancer Manag Res       Date:  2014-02-03       Impact factor: 3.989

8.  Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML).

Authors:  Jörg Tomeczkowski; Ansgar Lange; Andreas Güntert; Pushpike Thilakarathne; Joris Diels; Liang Xiu; Peter De Porre; Christoph Tapprich
Journal:  Adv Ther       Date:  2015-09-14       Impact factor: 3.845

9.  MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.

Authors:  Ashujit Tagde; Hasan Rajabi; Dina Stroopinsky; Reddy Gali; Maroof Alam; Audrey Bouillez; Surender Kharbanda; Richard Stone; David Avigan; Donald Kufe
Journal:  Oncotarget       Date:  2016-06-28

Review 10.  Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.

Authors:  Dilana Staudt; Heather C Murray; Tabitha McLachlan; Frank Alvaro; Anoop K Enjeti; Nicole M Verrills; Matthew D Dun
Journal:  Int J Mol Sci       Date:  2018-10-16       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.